5YKP
Human methionine aminopeptidase type 1b (F309M mutant) in complex with ovalicin
5YKP の概要
エントリーDOI | 10.2210/pdb5ykp/pdb |
分子名称 | Methionine aminopeptidase 1, COBALT (II) ION, POTASSIUM ION, ... (5 entities in total) |
機能のキーワード | selective inhibition, streptococcal pneumoniae, enterococcus feacalis, metal binding protein |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 34774.31 |
構造登録者 | |
主引用文献 | Pillalamarri, V.,Arya, T.,Haque, N.,Bala, S.C.,Marapaka, A.K.,Addlagatta, A. Discovery of natural product ovalicin sensitive type 1 methionine aminopeptidases: molecular and structural basis. Biochem. J., 476:991-1003, 2019 Cited by PubMed Abstract: Natural product ovalicin and its synthetic derivative TNP-470 have been extensively studied for their antiangiogenic property, and the later reached phase 3 clinical trials. They covalently modify the conserved histidine in Type 2 methionine aminopeptidases (MetAPs) at nanomolar concentrations. Even though a similar mechanism is possible in Type 1 human MetAP, it is inhibited only at millimolar concentration. In this study, we have discovered two Type 1 wild-type MetAPs ( and ) that are inhibited at low micromolar to nanomolar concentrations and established the molecular mechanism. F309 in the active site of Type 1 human MetAP (MetAP1b) seems to be the key to the resistance, while newly identified ovalicin sensitive Type 1 MetAPs have a methionine or isoleucine at this position. Type 2 human MetAP (MetAP2) also has isoleucine (I338) in the analogous position. Ovalicin inhibited F309M and F309I mutants of human MetAP1b at low micromolar concentration. Molecular dynamics simulations suggest that ovalicin is not stably placed in the active site of wild-type MetAP1b before the covalent modification. In the case of F309M mutant and human Type 2 MetAP, molecule spends more time in the active site providing time for covalent modification. PubMed: 30837307DOI: 10.1042/BCJ20180874 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.68 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード